Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Inflammatory Bowel Diseases

  Free Subscription


Articles published in Eur J Gastroenterol Hepatol

Retrieve available abstracts of 169 articles:
HTML format



Single Articles


    July 2024
  1. OZTURK O, Celebi G, Duman UG, Kupcuk E, et al
    Short-chain fatty acid levels in stools of patients with inflammatory bowel disease are lower than those in healthy subjects.
    Eur J Gastroenterol Hepatol. 2024;36:890-896.
    PubMed     Abstract available


    June 2024
  2. CHHIBBA T, Wong ECL, Reinisch W, Targownik L, et al
    Comparing the efficacy of vedolizumab between males and females: a post-hoc analysis of GEMINI-1 and VARSITY.
    Eur J Gastroenterol Hepatol. 2024;36:704-711.
    PubMed     Abstract available


    May 2024
  3. FREEMAN HJ
    Osteonecrosis (avascular necrosis) in inflammatory bowel disease: an extraintestinal clinical feature, not caused by corticosteroids.
    Eur J Gastroenterol Hepatol. 2024;36:503-504.
    PubMed    


    April 2024
  4. YUAN B, Huang P, Yang M, Tang G, et al
    Intestinal ultrasound scan predicts corticosteroid failure and colectomy risk in patients with ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2024 Apr 17. doi: 10.1097/MEG.0000000000002780.
    PubMed     Abstract available


  5. WESTON F, Carter B, Powell N, Young AH, et al
    Antidepressant treatment in inflammatory bowel disease: a systematic review and meta-analysis.
    Eur J Gastroenterol Hepatol. 2024 Apr 5. doi: 10.1097/MEG.0000000000002768.
    PubMed     Abstract available


  6. SUN Z, Cao L, Chen Y, Zhu W, et al
    Long-term outcomes of intestinal penetrating Crohn's disease following successful nonoperative management.
    Eur J Gastroenterol Hepatol. 2024 Apr 5. doi: 10.1097/MEG.0000000000002775.
    PubMed     Abstract available


  7. TEPES K, Hanzel J, Stubljar D, Strmsek K, et al
    Biological treatment approach to inflammatory bowel disease is similar in academic and nonacademic centres - prime time for decentralisation of inflammatory bowel disease care?
    Eur J Gastroenterol Hepatol. 2024 Apr 2. doi: 10.1097/MEG.0000000000002771.
    PubMed     Abstract available


  8. D'HAENS G, Baert F, Danese S, Kobayashi T, et al
    Efficacy of vedolizumab during intravenous induction therapy in ulcerative colitis and Crohn's disease: post hoc analysis of patient-reported outcomes from the VISIBLE 1 and 2 studies.
    Eur J Gastroenterol Hepatol. 2024;36:404-415.
    PubMed     Abstract available


  9. BAI Y, Sun Y, He Q, Bai X, et al
    Comparative effectiveness and safety of ustekinumab at different intervals of maintenance phase in inflammatory bowel disease: a systematic review and meta-analysis.
    Eur J Gastroenterol Hepatol. 2024;36:359-370.
    PubMed     Abstract available


  10. KOSTEV K, Roderburg C, Loosen SH
    Inflammatory bowel disease is associated with multiple sclerosis or Hodgkin lymphoma.
    Eur J Gastroenterol Hepatol. 2024;36:498.
    PubMed    


    March 2024
  11. ZAGOROWICZ E, Binowski G, Strzadala D, Pruszko C, et al
    Savings in social expenditures for work incapacity in patients with inflammatory bowel disease depend on access to innovative therapies in Poland.
    Eur J Gastroenterol Hepatol. 2024 Mar 19. doi: 10.1097/MEG.0000000000002764.
    PubMed     Abstract available


  12. ROKKAS T, Gisbert JP, Ekmektzoglou K, Dassopoulos T, et al
    Comparative maintenance performance of all biologic agents and small molecules in ulcerative colitis: a network meta-analysis.
    Eur J Gastroenterol Hepatol. 2024 Mar 12. doi: 10.1097/MEG.0000000000002751.
    PubMed     Abstract available


  13. STEPHENS IJB, Murphy B, Burns L, McCawley N, et al
    Contemporary perioperative outcomes after total abdominal colectomy for ulcerative colitis in a tertiary referral centre.
    Eur J Gastroenterol Hepatol. 2024 Mar 11. doi: 10.1097/MEG.0000000000002755.
    PubMed     Abstract available


  14. MOGILEVSKI T, Nguyen AL, Ajamian M, Smith R, et al
    Intestinal barrier biomarkers in clinical evaluation of patients with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2024;36:271-280.
    PubMed     Abstract available


  15. FIORINO G, Colombel JF, Katsanos K, Mearin F, et al
    Iron therapy supplementation in inflammatory bowel disease patients with iron deficiency anemia: findings from a real-world analysis in Italy.
    Eur J Gastroenterol Hepatol. 2024 Mar 1. doi: 10.1097/MEG.0000000000002740.
    PubMed     Abstract available


    February 2024
  16. BHAYANA H, Sharma TK, Sharma A, Dhillon MS, et al
    Osteonecrosis in patients with inflammatory bowel disease: a systematic review and meta-analysis.
    Eur J Gastroenterol Hepatol. 2024 Feb 21. doi: 10.1097/MEG.0000000000002735.
    PubMed     Abstract available


    January 2024
  17. KIRKIK D, Kalkanli Tas S, Tanoglu A
    Unraveling the blood microbiome: novel insights into inflammasome responses in Crohn's disease.
    Eur J Gastroenterol Hepatol. 2024 Jan 22. doi: 10.1097/MEG.0000000000002695.
    PubMed     Abstract available


    December 2023
  18. MANTZARIS GJ, Bressler B, Adsul S, Luo M, et al
    Effectiveness and safety of vedolizumab and infliximab in biologic-naive patients with Crohn's disease: results from the EVOLVE study.
    Eur J Gastroenterol Hepatol. 2023 Dec 27. doi: 10.1097/MEG.0000000000002690.
    PubMed     Abstract available


  19. VIAZIS N, Manolakis A, Vraka M, Mylonas I, et al
    Anal defecatory function in ulcerative colitis patients after total proctocolectomy and ileal pouch-anal anastomosis: a prospective cohort study.
    Eur J Gastroenterol Hepatol. 2023 Dec 27. doi: 10.1097/MEG.0000000000002706.
    PubMed     Abstract available


  20. SONNENBERG A, Duong HT, McCarty DJ, El-Serag HB, et al
    Concurrence of inflammatory bowel disease with multiple sclerosis or Hodgkin lymphoma.
    Eur J Gastroenterol Hepatol. 2023;35:1349-1353.
    PubMed     Abstract available


  21. STJARNGRIM J, Ekbom A, Widman L, Hultcrantz R, et al
    Post-colonoscopy rectal cancer in Swedish patients with Crohn's disease 2001-2015: a population-based case review study.
    Eur J Gastroenterol Hepatol. 2023;35:1334-1340.
    PubMed     Abstract available


    November 2023
  22. NGUYEN AL, Herath M, Burns M, Holt D, et al
    The value of whole-body dual-energy x-ray absorptiometry in assessing body composition in patients with inflammatory bowel disease: a prospective study.
    Eur J Gastroenterol Hepatol. 2023 Nov 7. doi: 10.1097/MEG.0000000000002675.
    PubMed     Abstract available


    October 2023
  23. LIU C, Liu X, Shi H, Chen F, et al
    The correlation between serum 25-hydroxyvitamin D level and ulcerative colitis: a systematic review and meta-analysis.
    Eur J Gastroenterol Hepatol. 2023 Oct 18. doi: 10.1097/MEG.0000000000002670.
    PubMed     Abstract available


  24. BARAUNA FSB, Magro DO, Miranda EF, Marcal GN, et al
    Correlation between trough levels of infliximab and postoperative endoscopic recurrence in Crohn's disease patients submitted to ileocolonic resections.
    Eur J Gastroenterol Hepatol. 2023 Oct 6. doi: 10.1097/MEG.0000000000002639.
    PubMed     Abstract available


  25. VALIBOUZE C, Nachury M, Hambli S, Desreumaux P, et al
    Alternative to subtotal colectomy for pregnant woman with medically refractory acute severe ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2023;35:1230.
    PubMed    


  26. JANSEN FM, den Broeder N, Lubeek SFK, Savelkoul EHJ, et al
    Cumulative thiopurine dosing and keratinocyte skin cancer in inflammatory bowel disease: a case-control study.
    Eur J Gastroenterol Hepatol. 2023;35:1123-1130.
    PubMed     Abstract available


    September 2023
  27. FERRARO S, Cappello E, Bartolini C, Convertino I, et al
    Potential missed diagnoses of Crohn's disease in tertiary care: impact on drug utilization and healthcare facilities use.
    Eur J Gastroenterol Hepatol. 2023 Sep 18. doi: 10.1097/MEG.0000000000002642.
    PubMed     Abstract available


  28. ALHALABI M, Alaa Eddin K, Abbas A
    Therapeutic effects of biological treatments on AA amyloidosis associated with inflammatory bowel disease: a case report and literature review.
    Eur J Gastroenterol Hepatol. 2023 Sep 18. doi: 10.1097/MEG.0000000000002649.
    PubMed     Abstract available


  29. HONAP S, Irving PM, Samaan MA
    JAK inhibitors for the treatment of inflammatory bowel disease: results of an international survey of perceptions, attitudes, and clinical practice.
    Eur J Gastroenterol Hepatol. 2023 Sep 18. doi: 10.1097/MEG.0000000000002650.
    PubMed     Abstract available


  30. NERI B, D'Agostini G, Salvatori S, Mossa M, et al
    Severe acute respiratory syndrome coronavirus 2 infection does not worsen the course of inflammatory bowel disease in the long term.
    Eur J Gastroenterol Hepatol. 2023;35:948-954.
    PubMed     Abstract available


    August 2023
  31. ZHANG T, Zhang QD, Jin T, Li WJ, et al
    Is histological healing more clinically valuable than endoscopic healing in Crohn's disease?
    Eur J Gastroenterol Hepatol. 2023 Aug 14. doi: 10.1097/MEG.0000000000002624.
    PubMed     Abstract available


  32. TSAFARIDOU M, Augoustaki A, Koutroubakis I
    Lymphogranuloma venereum and CMV co-infection mimicking ulcerative proctitis in a non-immunocompromised patient.
    Eur J Gastroenterol Hepatol. 2023;35:921-922.
    PubMed    


  33. HUANG Y, Su Y, Qin R, Wang L, et al
    Mechanism by which oleracein E alleviates TNBS-induced ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2023;35:854-864.
    PubMed     Abstract available


    July 2023
  34. LYKOWSKA-SZUBER L, Walczak M, Dobrowolska A, Skrzypczak-Zielinska M, et al
    Apoptosis and inflammatory genes variants in primary non-response to anti-TNF therapy in Crohn's disease patients.
    Eur J Gastroenterol Hepatol. 2023 Jul 31. doi: 10.1097/MEG.0000000000002618.
    PubMed     Abstract available


  35. ZHAN Y, Cheng X, Mei P, Wu J, et al
    Risk and incidence of colorectal stricture progressing to colorectal neoplasia in patients with inflammatory bowel disease: a systematic review and meta-analysis.
    Eur J Gastroenterol Hepatol. 2023 Jul 31. doi: 10.1097/MEG.0000000000002614.
    PubMed     Abstract available


  36. BOUSTANY A, Rahhal R, Mitri J, Onwuzo S, et al
    The impact of nonalcoholic fatty liver disease on inflammatory bowel disease-related hospitalization outcomes: a systematic review.
    Eur J Gastroenterol Hepatol. 2023 Jul 11. doi: 10.1097/MEG.0000000000002607.
    PubMed     Abstract available


    May 2023
  37. KONSTANTINOU CS, Korantzopoulos P, Fousekis FS, Katsanos KH, et al
    Inflammatory bowel disease and atrial fibrillation: a contemporary overview.
    Eur J Gastroenterol Hepatol. 2023 May 8. doi: 10.1097/MEG.0000000000002562.
    PubMed     Abstract available


  38. HASSAN EA, Abdel Rehim ASE, Ahmed AO, Salim SMAE, et al
    Current insight into enteropathogens in flare-up ulcerative colitis. An observational study.
    Eur J Gastroenterol Hepatol. 2023 May 3. doi: 10.1097/MEG.0000000000002563.
    PubMed     Abstract available


  39. PRENTICE RE, Wright EK, Flanagan E, Kamm MA, et al
    Evaluation and management of ileal pouch-anal anastamosis (IPAA) complications in pregnancy, and the impacts of an IPAA on fertility.
    Eur J Gastroenterol Hepatol. 2023;35:609-612.
    PubMed     Abstract available


    April 2023
  40. CHAHAL JK, Sriranganathan D, Poo S, Lo SW, et al
    Network meta-analysis: efficacy and safety of treatments for fistulising Crohn's disease.
    Eur J Gastroenterol Hepatol. 2023 Apr 11. doi: 10.1097/MEG.0000000000002552.
    PubMed     Abstract available


  41. PRINCIPI M, Macaluso FS, Todeschini A, Facciotti F, et al
    Safety, hesitancy of coronavirus disease 2019 vaccination and pandemic burden in patients with inflammatory bowel disease: data of a national study (ESCAPE-IBD).
    Eur J Gastroenterol Hepatol. 2023 Apr 4. doi: 10.1097/MEG.0000000000002550.
    PubMed     Abstract available


  42. FARIA LM, Oliveira MM, Faria AA, Vasconcellos AVO, et al
    Late onset vedolizumab-induced eosinophilic pneumonia in a patient with ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2023;35:513-514.
    PubMed    


  43. KOKKOTIS G, Zampeli E, Tzouvala M, Giotis I, et al
    Prevalence and predictors of arthralgia after initiation of vedolizumab in patients with inflammatory bowel disease: a retrospective cohort study.
    Eur J Gastroenterol Hepatol. 2023;35:371-375.
    PubMed     Abstract available


    March 2023
  44. NOVAK G, Sever N, Hanzel J, Kozelj M, et al
    Biopsies from ulcer edge yield higher histological activity scores than biopsies from non-ulcerated mucosa in active ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2023 Mar 20. doi: 10.1097/MEG.0000000000002543.
    PubMed     Abstract available


  45. STJARNGRIM J, Widman L, Schmidt PT, Ekbom A, et al
    Post-endoscopy colorectal cancer after colectomy in inflammatory bowel disease patients: a population-based register study.
    Eur J Gastroenterol Hepatol. 2023;35:288-293.
    PubMed     Abstract available


  46. XUE M, Chen J, Zheng W, Liu Y, et al
    Clinical characteristics and quality of life in patients with inflammatory bowel disease-associated anemia in Southeast China.
    Eur J Gastroenterol Hepatol. 2023;35:275-284.
    PubMed     Abstract available


  47. SAYED A, Assis DN, Silveira MG, Deng Y, et al
    Outcomes of immunomodulator and advanced therapies for primary sclerosing cholangitis-associated inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2023;35:270-274.
    PubMed     Abstract available


  48. THOMAS PWA, van Caem M, West RL, Russel MGVM, et al
    Long-term effectiveness and safety of ustekinumab in Crohn's disease: a prospective cohort study.
    Eur J Gastroenterol Hepatol. 2023;35:261-269.
    PubMed     Abstract available


  49. LOOSEN SH, Kostev K, Scholer D, Orth HM, et al
    Infectious mononucleosis is associated with an increased incidence of Crohn's disease: results from a cohort study of 31 862 outpatients in Germany.
    Eur J Gastroenterol Hepatol. 2023;35:255-260.
    PubMed     Abstract available


  50. TANDON P, Natt N, Malhi G, Wong EC, et al
    Clinical remission in paired phase two and three studies in inflammatory bowel disease: a systematic review with meta-analysis.
    Eur J Gastroenterol Hepatol. 2023;35:231-240.
    PubMed     Abstract available


    February 2023
  51. SCALVINI D, Schiepatti A, Maimaris S, Cosentini E, et al
    Humoral immunogenicity of COVID-19 vaccines in patients with coeliac disease and other noncoeliac enteropathies compared to healthy controls.
    Eur J Gastroenterol Hepatol. 2023;35:167-173.
    PubMed     Abstract available


    January 2023
  52. TEN BOKKEL HUININK S, Beelen EMJ, Ten Bokkel Huinink T, Hoentjen F, et al
    Retreatment with anti-tumor necrosis factor therapy in combination with an immunomodulator for recurrence of Crohn's disease after ileocecal resection results in prolonged continuation as compared to anti-tumor necrosis factor monotherapy.
    Eur J Gastroenterol Hepatol. 2023;35:45-51.
    PubMed     Abstract available


    December 2022
  53. FOUSEKIS FS, Katsanos KH, Popovic DD
    Translation and validation of questionnaires: necessary processes for inflammatory bowel disease studies reliability.
    Eur J Gastroenterol Hepatol. 2022;34:1201-1202.
    PubMed    


  54. NARULA N, Wong ECL, Moayyedi P, Reinisch W, et al
    Pilot study of an elimination diet in adults with mild to moderate Crohn's disease.
    Eur J Gastroenterol Hepatol. 2022;34:1210-1219.
    PubMed     Abstract available


    November 2022
  55. FISKE J, Liu E, Limdi JK, Conley TE, et al
    Safety and effectiveness of ustekinumab in elderly Crohn's disease patients.
    Eur J Gastroenterol Hepatol. 2022;34:1132-1139.
    PubMed     Abstract available


  56. EBERL A, Qadri S, Saavalainen P, Sipponen T, et al
    Higher serum infliximab concentrations during induction predict short-term endoscopic response in patients with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2022;34:1125-1131.
    PubMed     Abstract available


    October 2022
  57. MARTINHO-GRUEBER M, Kapoglou I, Bravo F, Sarraj R, et al
    Alcohol and cannabis consumption in patients with inflammatory bowel disease: prevalence, pattern of consumption and impact on the disease.
    Eur J Gastroenterol Hepatol. 2022 Oct 26. pii: 00042737-990000000-00082.
    PubMed     Abstract available


  58. MOENS A, Alsoud D, Verstockt B, Sabino J, et al
    Adalimumab versus ustekinumab as first-line biological in moderate-to-severe Crohn's disease: real-life cohort from a tertiary referral center.
    Eur J Gastroenterol Hepatol. 2022;34:1015-1020.
    PubMed     Abstract available


  59. TEN BOKKEL HUININK S, de Jong DC, Nieboer D, Thomassen D, et al
    Validation and update of a prediction model for risk of relapse after cessation of anti-TNF treatment in Crohn's disease.
    Eur J Gastroenterol Hepatol. 2022;34:983-992.
    PubMed     Abstract available


    September 2022
  60. CASSINOTTI A, Mezzina N, De Silvestri A, Di Paolo D, et al
    Continuous clinical remission with biologics in ulcerative colitis: the 'AURORA' comparison study.
    Eur J Gastroenterol Hepatol. 2022 Sep 23. pii: 00042737-990000000-00076.
    PubMed     Abstract available


  61. EBERL A, Qadri S, Saavalainen P, Sipponen T, et al
    Higher serum infliximab concentrations during induction predict short-term endoscopic response in patients with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2022 Sep 12. pii: 00042737-990000000-00059.
    PubMed     Abstract available


  62. THEODORAKI E, Orfanoudaki E, Petroulaki E, Foteinogiannopoulou K, et al
    Active smoking is associated with the development of adverse events of biological therapy in patients with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2022 Sep 12. pii: 00042737-990000000-00073.
    PubMed     Abstract available


  63. PAUPARD T, Gonzalez F, Caron B, Siproudhis L, et al
    Real-world evidence of quality of life improvement in patients with distal ulcerative colitis treated by mesalazine: the Quartz study.
    Eur J Gastroenterol Hepatol. 2022 Sep 12. pii: 00042737-990000000-00067.
    PubMed     Abstract available


  64. ROBERTS CM, Gamwell KL, Baudino MN, Edwards CS, et al
    Illness stigma, body image dissatisfaction, thwarted belongingness and depressive symptoms in youth with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2022;34:919-924.
    PubMed     Abstract available


    August 2022
  65. TURSI A, Lopetuso LR, Vetrone LM, Gasbarrini A, et al
    SARS-CoV-2 infection as a potential trigger factor for de novo occurrence of inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2022;34:883-884.
    PubMed    


  66. WEWER MD, Karstensen JG, Burisch J
    Endoscopic small bowel balloon dilations in patients with Crohn's disease: a Danish nationwide cohort study, 1997-2015.
    Eur J Gastroenterol Hepatol. 2022;34:831-837.
    PubMed     Abstract available


    July 2022
  67. ZHU F, Qin Y, Wang Y, Zhang F, et al
    Critical roles of RGS16 in the mucosal inflammation of ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2022 Jul 14. pii: 00042737-990000000-00034.
    PubMed     Abstract available


  68. DIPASQUALE V, Pellegrino S, Ventimiglia M, Cucinotta U, et al
    Real-life experience of infliximab biosimilar in pediatric-onset inflammatory bowel disease: data from the Sicilian Network for Inflammatory Bowel Disease.
    Eur J Gastroenterol Hepatol. 2022 Jul 14. pii: 00042737-990000000-00036.
    PubMed     Abstract available


  69. GIRI S, Ingawale S
    Use of restrictive iron transfusion strategy in inflammatory bowel disease: one size does not fit all.
    Eur J Gastroenterol Hepatol. 2022;34:807.
    PubMed    


  70. GROVA M, Crispino F, Maida M, Macaluso FS, et al
    Authors' reply to 'Use of restrictive iron transfusion strategy in IBD: one size does not fit all'.
    Eur J Gastroenterol Hepatol. 2022;34:808.
    PubMed    


    April 2022
  71. FERRANTE M, Schirbel A, Pierik MJ, Haas T, et al
    Patient-reported continuous clinical response to golimumab in adults with moderately to severely active ulcerative colitis: results from GO OBSERVE, a real-world European observational study.
    Eur J Gastroenterol Hepatol. 2022 Apr 8. pii: 00042737-990000000-00016.
    PubMed     Abstract available


  72. GOMOLLON F, Gisbert JP, Guerra I, Plaza R, et al
    Clinical characteristics and prognostic factors for Crohn's disease relapses using natural language processing and machine learning: a pilot study.
    Eur J Gastroenterol Hepatol. 2022;34:389-397.
    PubMed     Abstract available


  73. BODINI G, Demarzo MG, Djahandideh A, Ziola S, et al
    Therapeutic drug monitoring in Crohn's disease patients treated with anti-TNF: a comparison of two techniques.
    Eur J Gastroenterol Hepatol. 2022;34:382-388.
    PubMed     Abstract available


  74. HOWARD G, Weiner D, Bar-Or I, Levine A, et al
    Dual biologic therapy with Vedolizumab and Ustekinumab for refractory Crohn's disease in children.
    Eur J Gastroenterol Hepatol. 2022;34:372-374.
    PubMed     Abstract available


    March 2022
  75. SMITH RL, Taylor KM, Friedman AB, Gibson DJ, et al
    Early sonographic response to a new medical therapy is associated with future treatment response or failure in patients with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2022 Mar 29. pii: 00042737-990000000-00008.
    PubMed     Abstract available


  76. CHUCK W, Shadbolt BF, Nordin F, Subramaniam K, et al
    BMI is important in predicting the loss of response in inflammatory bowel disease patients on tumour necrosis factor-alpha inhibitors.
    Eur J Gastroenterol Hepatol. 2022 Mar 29. pii: 00042737-990000000-00002.
    PubMed     Abstract available


  77. YOSHIDA A, Kimura K, Morizane T, Ueno F, et al
    Predictor of primary response to antitumor necrosis factor-alpha therapy for inflammatory bowel disease: a single-center observational study.
    Eur J Gastroenterol Hepatol. 2022 Mar 29. pii: 00042737-990000000-00007.
    PubMed     Abstract available


  78. LEI N, Kong P, Chen S, Wang Q, et al
    Upregulated NORAD is implicated in apoptosis, inflammation, and oxidative stress in ulcerative colitis through the nuclear factor-kappaappaB signaling.
    Eur J Gastroenterol Hepatol. 2022 Mar 29. pii: 00042737-990000000-00004.
    PubMed     Abstract available


  79. POO S, Sriranganathan D, Segal JP
    Network meta-analysis: efficacy of treatment for acute, chronic, and prevention of pouchitis in ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2022 Mar 9. pii: 00042737-900000000-97083.
    PubMed     Abstract available


  80. DAWRA S, Manrai M, Kumar A, Kumar S, et al
    Hyperbaric oxygen therapy in inflammatory bowel disease: a systemic review and meta-analysis.
    Eur J Gastroenterol Hepatol. 2022;34:359-360.
    PubMed    


  81. TUN GSZ, Robinson K, Marshall L, Wright A, et al
    The effect of infliximab dose escalation in inflammatory bowel disease patients with antibodies to infliximab.
    Eur J Gastroenterol Hepatol. 2022;34:295-301.
    PubMed     Abstract available


    February 2022
  82. FALLING CL, Stebbings S, David Baxter G, Siegel CA, et al
    Somatosensory assessments in patients with inflammatory bowel disease: a cross-sectional study examining pain processing pathways and the role of multiple patient factors.
    Eur J Gastroenterol Hepatol. 2022 Feb 14. pii: 00042737-900000000-97087.
    PubMed     Abstract available


    January 2022
  83. GROVA M, Crispino F, Maida M, Renna S, et al
    Effectiveness and safety of an on-demand ferric carboxymaltose infusion strategy in patients with inflammatory bowel disease: a real world experience.
    Eur J Gastroenterol Hepatol. 2022 Jan 31. pii: 00042737-900000000-97093.
    PubMed     Abstract available


  84. GIANNOS P, Triantafyllidis KK, Giannos G, Kechagias KS, et al
    SPP1 in infliximab resistant ulcerative colitis and associated colorectal cancer: an analysis of differentially expressed genes.
    Eur J Gastroenterol Hepatol. 2022 Jan 31. pii: 00042737-900000000-97092.
    PubMed     Abstract available


  85. KRUIS W, Leifeld L
    Response to: Malignancy associated to perianal Chrohn s fistula - a challenge for more clinical research.
    Eur J Gastroenterol Hepatol. 2022;34:9-10.
    PubMed    


  86. ADEGBOLA SO, Sarafian M, Sahnan K, Pechlivanis A, et al
    Lack of anti-TNF drugs levels in fistula tissue - a reason for nonresponse in Crohn's perianal fistulating disease?
    Eur J Gastroenterol Hepatol. 2022;34:18-26.
    PubMed     Abstract available


    December 2021
  87. THOMAS PWA, Smits LJT, Te Groen M, West RL, et al
    De-escalation of biological therapy in inflammatory bowel disease patients following prior dose escalation.
    Eur J Gastroenterol Hepatol. 2021 Dec 30. pii: 00042737-900000000-97101.
    PubMed     Abstract available


  88. GUILLO L, Bonnaud G, Nahon S, Caron B, et al
    French experience with telemedicine in inflammatory bowel disease: a patients and physicians survey.
    Eur J Gastroenterol Hepatol. 2021 Dec 3. pii: 00042737-900000000-97115.
    PubMed     Abstract available


  89. GOODDAY SM, Travis S, Walsh A, Friend SH, et al
    Stress-related consequences of the coronavirus disease 2019 pandemic on symptoms of Crohn's disease.
    Eur J Gastroenterol Hepatol. 2021;33:1511-1516.
    PubMed     Abstract available


  90. ADEGBOLA SO, Sarafian M, Sahnan K, Ding NS, et al
    Differences in amino acid and lipid metabolism distinguish Crohn's from idiopathic/cryptoglandular perianal fistulas by tissue metabonomic profiling and may offer clues to underlying pathogenesis.
    Eur J Gastroenterol Hepatol. 2021;33:1469-1479.
    PubMed     Abstract available


  91. SINGH AK, Kumar-M P, Sharma V
    Hyperbaric oxygen therapy for ulcerative colitis: conflicting evidence from randomized trials.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed    


  92. TURSI A
    Performances of anti-TNFalpha antibodies as long-term maintenance therapy for ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed    


  93. MOURAD FH, Leong RW, Kariyawasam VC
    Early thiopurine maintenance and reduced colectomy rate in ulcerative colitis: fact or fiction?
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed    


  94. NG A
    Mind the lipids: hyperlipidaemia resultant from JAK inhibitor use in inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed    


  95. NG A
    Early thiopurine maintenance and reduced colectomy rate in ulcerative colitis: fact or fiction?
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed    


  96. NG A
    The efficacy of tumour necrosis factor-alpha antagonists in maintenance therapy for ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed    


  97. GARRIDO I, Santos AL, Lopes J, Lopes S, et al
    "Hepatotoxicity in inflammatory bowel disease: mesalazine, the forgotten drug".
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed     Abstract available


  98. DING NS, Lee T, Bettenworth D, Cleynen I, et al
    Assessing aCCess to Investigations in Inflammatory Bowel Disease (ACCID): results from an international survey.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed     Abstract available


  99. INNOCENTI T, Roselli J, Lynch EN, Apolito P, et al
    Infectious risk of vedolizumab compared with other biological agents in the treatment of inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed     Abstract available


  100. VIOLA A, Muscianisi M, Voti RL, Costantino G, et al
    Predictors of Covid-19 vaccination acceptance in IBD patients: a prospective study.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed     Abstract available


  101. HILARY K, Carthage M, Jawad R, Karen B, et al
    Lost in words? The readability of medication information sheets in commonly used medication in inflammatory bowel diseases.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed    


  102. NG A
    Histological subtypes of perianal fistula-associated malignancies in Crohn's disease.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed    


  103. SILVA MENDES S, Ferreira P, Antunes P, Goncalves M, et al
    Validation of the IBD-Disk in a Portuguese cohort.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed     Abstract available


  104. LI X, Wang Y, Ge T, Xiao Y, et al
    Henoch-Schonlein purpura associated with infliximab therapy for pediatric Crohn's disease.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed    


  105. HANZEL J, Kozelj M, Spes Hlastec A, Kurent T, et al
    Ustekinumab concentrations shortly after escalation to monthly dosing may identify endoscopic remission in refractory Crohn's disease.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed     Abstract available


  106. TEN BOKKEL HUININK S, Biemans V, Duijvestein M, Pierik M, et al
    Re-induction with intravenous Ustekinumab after secondary loss of response is a valid optimization strategy in Crohn's disease.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed     Abstract available


  107. PIAZZOLLA M, Marmo R, Terracciano F, Perri F, et al
    Asymptomatic retention of fragmented small bowel capsule endoscopy retrieved by retrograde double-balloon enteroscopy in Crohn's disease.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed    


  108. SALVATORI S, Marafini I, Monteleone G
    Paradoxical hidradenitis suppurativa in Crohn's disease patients receiving infliximab: a case report and review of literature.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed     Abstract available


  109. LI T, Gao L, Cao L, Guo Z, et al
    Changes in disease behaviour and location and factor analysis in patients with Crohn's disease undergoing repeated-resections.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed     Abstract available


  110. CROCETTI E, Bergamaschi W, Russo AG
    Population-based incidence and prevalence of inflammatory bowel diseases in Milan (Northern Italy), and estimates for Italy.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed     Abstract available


  111. WALSHE M, Borowski K, Boland K, Rho S, et al
    Ustekinumab induction concentrations are associated with clinical and biochemical outcomes at week 12 of treatment in Crohn's disease.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed     Abstract available


    November 2021
  112. YAO J, Gao R, Luo M, Li D, et al
    Long noncoding RNA KIF9-AS1 promotes cell apoptosis by targeting the microRNA-148a-3p/suppressor of cytokine signaling axis in inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2021 Nov 8. pii: 00042737-900000000-97127.
    PubMed     Abstract available


  113. TURSI A, Florio T, Tiano M
    Successful treatment of concomitant Crohn's disease and psoriasis with risankizumab.
    Eur J Gastroenterol Hepatol. 2021;33:1462-1464.
    PubMed    


  114. PUTIGNANI L, Oliva S, Isoldi S, Del Chierico F, et al
    Fecal and mucosal microbiota profiling in pediatric inflammatory bowel diseases.
    Eur J Gastroenterol Hepatol. 2021;33:1376-1386.
    PubMed     Abstract available


    October 2021
  115. SHAMSEYA AM, Hussein WM, Elnely DA, Adel F, et al
    Serum matrix metalloproteinase-9 concentration as a marker of disease activity in patients with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2021 Oct 20. pii: 00042737-900000000-97135.
    PubMed     Abstract available


  116. VELAYOS JIMENEZ B, Del Olmo Martinez L, Macho Conesa A, Fernandez Salazar L, et al
    Should the birth month be considered as one of the possible environmental risk factors in the pathogenesis of inflammatory bowel disease?
    Eur J Gastroenterol Hepatol. 2021;33:1332.
    PubMed    


  117. GREENER T, Boland K, Milgrom R, Ben-Bassat O, et al
    Higher adalimumab maintenance regimen is more effective than standard dose in anti-TNF experienced Crohn's disease patients.
    Eur J Gastroenterol Hepatol. 2021;33:1274-1279.
    PubMed     Abstract available


    August 2021
  118. BAMIAS G, Kokkotis G, Christidou A, Christodoulou DK, et al
    The natural history of COVID-19 in patients with inflammatory bowel disease: a nationwide study by the Hellenic Society for the study of IBD.
    Eur J Gastroenterol Hepatol. 2021 Aug 16. pii: 00042737-900000000-97160.
    PubMed     Abstract available


  119. KARIMI N, Sechi AJ, Harb M, Sawyer E, et al
    The effect of a nurse-led advice line and virtual clinic on inflammatory bowel disease service delivery: an Australian study.
    Eur J Gastroenterol Hepatol. 2021 Aug 16. pii: 00042737-900000000-97158.
    PubMed     Abstract available


  120. CAPRIOLI F, Daperno M, Bravata I, Brigido A, et al
    Who are the patients with Crohn's disease unsuitable to receive an anti-TNFalpha therapy? Results from a survey of Italian physicians and literature review.
    Eur J Gastroenterol Hepatol. 2021;33:1082-1090.
    PubMed     Abstract available


  121. GONG W, Guo K, Zheng T, Xie H, et al
    JINLING (Judicious INdex of Luminal INflammation Grade) score, an effective indicator to assess inflammation severity in Crohn's disease.
    Eur J Gastroenterol Hepatol. 2021;33:1049-1054.
    PubMed     Abstract available


    July 2021
  122. SMITH RL, Taylor KM, Friedman AB, Su HY, et al
    Interrater reliability of the assessment of disease activity by gastrointestinal ultrasound in a prospective cohort of patients with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2021 Jul 30. pii: 00042737-900000000-97173.
    PubMed     Abstract available


  123. GONZALEZ-PARTIDA I, Martinez-Lozano H, Gonzalez-Lois C, Peligros I, et al
    Histological inflammatory activity can predict endoscopic relapse in patients with ulcerative colitis who have achieved mucosal healing.
    Eur J Gastroenterol Hepatol. 2021 Jul 30. pii: 00042737-900000000-97168.
    PubMed     Abstract available


  124. ORFANOUDAKI E, Drygiannakis I, Theodoraki E, Foteinogiannopoulou K, et al
    Real-life utility and diagnostic accuracy of a home-performed fecal calprotectin test to predict endoscopic activity in patients with inflammatory bowel disease under maintenance treatment with adalimumab.
    Eur J Gastroenterol Hepatol. 2021 Jul 19. pii: 00042737-900000000-97178.
    PubMed     Abstract available


  125. CORTEGOSO VALDIVIA P, Elosua A, Houdeville C, Pennazio M, et al
    Clinical feasibility of panintestinal (or panenteric) capsule endoscopy: a systematic review.
    Eur J Gastroenterol Hepatol. 2021;33:949-955.
    PubMed     Abstract available


  126. NERI B, Scarozza P, Giannarelli D, Sena G, et al
    Efficacy and tolerability of very low-volume bowel preparation in patients with inflammatory bowel diseases.
    Eur J Gastroenterol Hepatol. 2021;33:977-982.
    PubMed     Abstract available


  127. LIVNE M, Amitai MM, Klang E, Ben Horin S, et al
    Qualitative sonographic assessment of transmural ileal inflammation in Crohn's disease: a comparison with MRI activity score.
    Eur J Gastroenterol Hepatol. 2021;33:961-966.
    PubMed     Abstract available


    June 2021
  128. RICHTER V, Bermont A, Cohen DL, Broide E, et al
    Effect of inflammatory bowel disease and related medications on COVID-19 incidence, disease severity, and outcome: the Israeli experience.
    Eur J Gastroenterol Hepatol. 2021 Jun 29. pii: 00042737-900000000-97186.
    PubMed     Abstract available


  129. ATTAUABI M, Vind I, Pedersen G, Bendtsen F, et al
    Short and long-term effectiveness and safety of vedolizumab in treatment-refractory patients with ulcerative colitis and Crohn's disease - a real-world two-center cohort study.
    Eur J Gastroenterol Hepatol. 2021 Jun 7. pii: 00042737-900000000-97194.
    PubMed     Abstract available


  130. LLAO J, Masnou H, Romero C, Bargallo A, et al
    Noninvasive assessment of liver fibrosis in Crohn's disease patients exposed to methotrexate.
    Eur J Gastroenterol Hepatol. 2021;33:794-798.
    PubMed     Abstract available


    May 2021
  131. RIZOS ED, Antonogiannaki EM, Chatzidakis A, Kallieri M, et al
    Vedolizumab-induced acute interstitial lung injury in a 39-year-old male with ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2021 May 31. pii: 00042737-900000000-97199.
    PubMed     Abstract available


  132. GATOPOULOU A, Christodoulou DK, Katsanos KH, Bakos D, et al
    Effect of golimumab on health-related quality of life, other patient-reported outcomes and healthcare resource utilization in patients with moderate-to-severe ulcerative colitis: a real-world multicenter, noninterventional, observational study in Gree
    Eur J Gastroenterol Hepatol. 2021 May 21. pii: 00042737-900000000-97217.
    PubMed     Abstract available


  133. VOHRA I, Attar B, Haghbin H, Mutneja H, et al
    Incidence and risk factors for 30-day readmission in ulcerative colitis: nationwide analysis in biologic era.
    Eur J Gastroenterol Hepatol. 2021 May 21. pii: 00042737-900000000-97210.
    PubMed     Abstract available


  134. ANGELINO G, Cifaldi C, Zangari P, Di Cesare S, et al
    Gastric cancer, inflammatory bowel disease and polyautoimmunity in a 17-year-old boy: CTLA-4 deficiency successfully treated with Abatacept.
    Eur J Gastroenterol Hepatol. 2021 May 21. pii: 00042737-900000000-97208.
    PubMed     Abstract available


  135. VAN GENNEP S, Gielen ME, Rietdijk ST, de Boer NKH, et al
    Work productivity loss is determined by fatigue and reduced quality of life in employed inflammatory bowel disease patients: a prospective multicentre cohort study.
    Eur J Gastroenterol Hepatol. 2021 May 3. doi: 10.1097/MEG.0000000000002178.
    PubMed     Abstract available


  136. VIGLIO A, Lenti MV, Vanoli A, Di Sabatino A, et al
    Rectal neuroendocrine cell proliferation in a patient with ulcerative colitis treated with adalimumab.
    Eur J Gastroenterol Hepatol. 2021;33:766-768.
    PubMed    


  137. TURSI A, Mocci G, Lorenzetti R, Allegretta L, et al
    Long-term real-life efficacy and safety of infliximab and adalimumab in the treatment of inflammatory bowel diseases outpatients.
    Eur J Gastroenterol Hepatol. 2021;33:670-679.
    PubMed     Abstract available


  138. FREITAS M, Curdia Goncalves T, Boal Carvalho P, Dias de Castro F, et al
    From terminal ileitis to Crohn's disease: how capsule endoscopy is crucial to diagnosis.
    Eur J Gastroenterol Hepatol. 2021;33:631-638.
    PubMed     Abstract available


    April 2021
  139. SINGH AK, Jha DK, Jena A, Kumar-M P, et al
    Hyperbaric oxygen therapy in inflammatory bowel disease: a systematic review and meta-analysis.
    Eur J Gastroenterol Hepatol. 2021 Apr 19. doi: 10.1097/MEG.0000000000002164.
    PubMed     Abstract available


  140. CORREIA JP, Ponte AI, Silva JC, Gomes AC, et al
    Mesalazine-induced acute pancreatitis: a rare adverse reaction but with important therapeutic implications in ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2021;33:595.
    PubMed    


  141. GONELLA F, Massucco P, Daperno M, Mineccia M, et al
    Ulcerative enteritis. How the extension of ulcerative colitis to small bowel may jeopardize postcolectomy course: a case report and literature review.
    Eur J Gastroenterol Hepatol. 2021;33:589-594.
    PubMed     Abstract available


  142. GOMES C, Pinho R, Ponte A, Silva JC, et al
    Patient's perspective on the implementation of measures to contain the SARS-CoV-2 pandemic in a Portuguese Gastroenterology Department.
    Eur J Gastroenterol Hepatol. 2021;33:527-532.
    PubMed     Abstract available


  143. TAMILARASAN AG, Krishnananthan T
    Faecal microbiota transplantation: what's beyond Clostridium difficile infection?
    Eur J Gastroenterol Hepatol. 2021;33:487-494.
    PubMed     Abstract available


    March 2021
  144. CROOKS B, Misra R, Arebi N, Kok K, et al
    The dietary practices and beliefs of people living with older-onset inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2021 Mar 18. pii: 00042737-900000000-97269.
    PubMed     Abstract available


  145. FERNANDES SR, Serrazina J, Rodrigues IC, Bernardo S, et al
    Proactive therapeutic drug monitoring is more effective than conventional management in inducing fecal calprotectin remission in inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2021 Mar 12. pii: 00042737-900000000-97288.
    PubMed     Abstract available


  146. KARIYAWASAM VC, Mourad FH, Mitrev N, Paramsothy S, et al
    Early thiopurine maintenance is associated with reduced proximal disease progression and colectomy rate in ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2021 Mar 12. pii: 00042737-900000000-97273.
    PubMed     Abstract available


  147. SCHARRER S, Kutschera M, Weseslindtner L, Primas C, et al
    Humoral response to COVID-19 infection in immunosuppressed patients with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2021;33:443-447.
    PubMed     Abstract available


  148. CANCADO GGL, Nardelli MJ, Gouthier MAD
    Adalimumab-induced leukocytoclastic vasculitis in a Crohn's disease patient.
    Eur J Gastroenterol Hepatol. 2021;33:453.
    PubMed    


  149. SHARMA V, Verma S, Kumar-M P, Mandavdhare HS, et al
    Serial measurements of faecal calprotectin may discriminate intestinal tuberculosis and Crohn's disease in patients started on antitubercular therapy.
    Eur J Gastroenterol Hepatol. 2021;33:334-338.
    PubMed     Abstract available


    February 2021
  150. KYRIAKOS N, Papaefthymiou A, Giakoumis M, Galanopoulos M, et al
    Prevalence of inflammatory bowel disease in young Greek Army male recruits from 2006 to 2018: a 13-year retrospective study from a tertiary center.
    Eur J Gastroenterol Hepatol. 2021 Feb 26. pii: 00042737-900000000-97290.
    PubMed     Abstract available


  151. LOVERO R, Losurdo G, La Fortezza RF, Terracciano F, et al
    Safety and efficacy of switching from infliximab biosimilar CT-P13 to infliximab biosimilar SB2 in patients with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2021;32:201-207.
    PubMed     Abstract available


  152. MANTAKA A, Tsoukali E, Fragaki M, Karmiris K, et al
    Reply to the letter to the Editor: 'The role of coexisting cardiovascular disease on disease severity in patients with inflammatory bowel disease'.
    Eur J Gastroenterol Hepatol. 2021;32:300-302.
    PubMed    


    January 2021
  153. KOUMAKI D, Machaira A, Katoulis AC, Bitados P, et al
    Mucocutaneous manifestations in patients with inflammatory bowel disease: a decade study from a Greek cohort.
    Eur J Gastroenterol Hepatol. 2021 Jan 18. pii: 00042737-900000000-97312.
    PubMed     Abstract available


  154. UNAL NG, Oruc N, Tomey O, Omer Ozutemiz A, et al
    Malnutrition and sarcopenia are prevalent among inflammatory bowel disease patients with clinical remission.
    Eur J Gastroenterol Hepatol. 2021 Jan 18. pii: 00042737-900000000-97311.
    PubMed     Abstract available


  155. MAGRI S, Chessa L, Demurtas M, Cabras F, et al
    Review article: safety of new biologic agents for inflammatory bowel disease in the liver.
    Eur J Gastroenterol Hepatol. 2021 Jan 18. pii: 00042737-900000000-97310.
    PubMed     Abstract available


  156. STRAATMIJER T, van Gennep S, Duijvestein M, Ponsioen CIJ, et al
    Real-world clinical and endoscopic outcomes after one year tofacitinib treatment in ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2021;Publish Ahead of Print.
    PubMed     Abstract available


  157. FIGUEREDO CM, Nunes JGR, Mello-Neto JM, Carvalho AT, et al
    Higher salivary expression of S100A12 in patients with ulcerative colitis and chronic periodontitis.
    Eur J Gastroenterol Hepatol. 2021;33:116-117.
    PubMed    


    November 2020
  158. WEISLINGER L, Guillo L, D'Amico F, Danese S, et al
    Knowledge of 5-aminosalicylic acid nephrotoxicity and adherence to kidney function monitoring of patients with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2020 Nov 30. doi: 10.1097/MEG.0000000000002008.
    PubMed     Abstract available


  159. LYUTAKOV I, Lozanov V, Sugareva P, Valkov H, et al
    Serum 7-alfa-hydroxy-4-cholesten-3-one and fibroblast growth factor-19 as biomarkers diagnosing bile acid malabsorption in microscopic colitis and inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2020 Nov 10. doi: 10.1097/MEG.0000000000001925.
    PubMed     Abstract available


  160. LYU L, Chen D, Yu M, Yang Y, et al
    The role of coexisting cardiovascular disease on disease severity in patients with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2020;32:1480-1481.
    PubMed    


    October 2020
  161. GILISSEN LPL, Tajzai R, Romberg M, Pierik M, et al
    The prevalence of nodular regenerative hyperplasia of the liver in long-term thiopurine-treated inflammatory bowel disease patients.
    Eur J Gastroenterol Hepatol. 2020 Oct 29. doi: 10.1097/MEG.0000000000001980.
    PubMed     Abstract available


  162. ROMEO S, Neri B, Mossa M, Calabrese E, et al
    Finger clubbing in inflammatory bowel disease: association with upper small bowel lesions and need of surgery in Crohn's disease.
    Eur J Gastroenterol Hepatol. 2020 Oct 29. doi: 10.1097/MEG.0000000000001966.
    PubMed     Abstract available


  163. KJAERGAARD S, Jensen TSR, Feddersen UR, Bindslev N, et al
    Decreased number of colonic tuft cells in quiescent ulcerative colitis patients.
    Eur J Gastroenterol Hepatol. 2020 Oct 16. doi: 10.1097/MEG.0000000000001959.
    PubMed     Abstract available


  164. MOOSVI Z, Duong J, Bechtold ML, Nguyen DL, et al
    Systematic review and meta-analysis: risks of postoperative complications with preoperative use of anti-tumor necrosis factor-alpha biologics in inflammatory bowel disease patients.
    Eur J Gastroenterol Hepatol. 2020 Oct 16. doi: 10.1097/MEG.0000000000001944.
    PubMed     Abstract available


  165. BHAMBHVANI HP, Zamora A
    Deep learning enabled classification of Mayo endoscopic subscore in patients with ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2020 Oct 16. doi: 10.1097/MEG.0000000000001952.
    PubMed     Abstract available


    September 2020
  166. LOPETUSO LR, Corbi M, Scaldaferri F, Petito V, et al
    Characterization of mucosal cytokine profile in ulcerative colitis patients under conventional and anti-TNF-a treatment.
    Eur J Gastroenterol Hepatol. 2020 Sep 23. doi: 10.1097/MEG.0000000000001933.
    PubMed     Abstract available


  167. VELLOPOULOU K, Stefanou G, Tzanetakos C, Boubouchairopoulou N, et al
    Cost-effectiveness of tofacitinib for the treatment of moderate to severe active ulcerative colitis in Greece.
    Eur J Gastroenterol Hepatol. 2020 Sep 23. doi: 10.1097/MEG.0000000000001916.
    PubMed     Abstract available


    May 2020
  168. OZKAN E, Basaranoglu M
    Recurrent 'gloves and socks' distribution with bullous eruptions after adalimumab and infliximab treatment in a patient with Crohn's disease.
    Eur J Gastroenterol Hepatol. 2020;32:666-667.
    PubMed    


    April 2020
  169. GUNEY M, Basaranoglu M
    A patient with Crohn's disease during remission by biological agent treatment developed active pulmonary tuberculosis and determining the eating habits.
    Eur J Gastroenterol Hepatol. 2020;32:541-542.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.